Curie Capital

Scientific breakthroughs can only benefit patients when promising ideas are developed into effective medicines and medical technologies. Curie Capital’s mission is to help bring those innovations to patients worldwide by investing in high-potential early-stage life sciences companies. Founded in 2018 and headquartered in Amsterdam, the firm invests at Seed and Series A in biotechnology, pharmaceutical and medical technology companies, with a focus on therapeutics, diagnostics, and class IIb and III medical devices.

Curie Capital typically acts as a lead investor and supports portfolio companies beyond providing capital. Its team of life sciences experts and business analysts works with founders through research and development, helping companies build teams, form investor syndicates, access advisors and reduce risk as they progress toward proof of concept or commercialization. The firm says its current fund invests in companies headquartered in the Netherlands that meet the applicable RVO seed capital criteria.